Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported
February 07 2022 - 3:01PM
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
company focused on the treatment of primary and metastatic cancers
of the liver, announced today that the Company has appointed
Anthony Dias as its new Vice President of Finance.
Mr. Dias brings over 20 years of experience leading finance
and operational teams at pharmaceutical, medical device and
technology companies. Mr. Dias will oversee all financial aspects
of the company, including financial planning and analysis,
financial reporting, accounting and control, tax, and treasury. He
will report directly to the Company's CEO, Gerard Michel.
"Delcath is pleased to welcome Tony as the new V.P. of Finance,”
said Gerard Michel, Chief Executive Officer. “Tony’s senior finance
expertise, experience at leading healthcare organizations, and
track record of success will be a great asset, as we focus on
commercialization and expanding into new indications."
Prior to Delcath, Anthony was the VP of Finance and Controller
for Advanced Group and PAREXEL, a public company CRO, helping the
sale of the company to private equity for $5.5 billion. Mr. Dias
was also the Senior Vice President and Chief Financial Officer
of SeaChange a public traded company providing video solutions and
VP Finance of LeMaitre Vascular, a medical device manufacturer,
where he helped lead the company’s Initial Public Offering in 2006.
Mr. Dias is a certified public accountant and worked at Arthur
Andersen, a multinational professional services firm.
Inducement Grants Under Nasdaq Listing Rule
5635(c)(4)
In connection with the appointment, Delcath has granted an
equity award to Mr. Anthony Dias, Delcath’s Vice President of
Finance, outside of the Company's Amended and Restated 2020 Stock
Incentive Plan and material to Mr. Dias’ acceptance of employment
with the company.
Mr. Dias received options to purchase 30,000 shares of Delcath
common stock. The options will be issued upon the employee's grant
date of February 7, 2022 (“Grant Date”), and all stock options
included within the equity inducement award will have an exercise
price equal to the closing price of Delcath common stock on the
Grant Date. One-third of the options will vest on the first
anniversary of the Grant Date with the remaining two thirds
(20,000) of the options vesting in equal monthly installments over
the 24-month period beginning on the first anniversary of the
employment commencement date for Mr. Dias (1/24th will vest on the
first day of each month during said 24-month period, provided that
Mr. Dias remains employed as of each such vesting date). The
options have a ten-year term.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company’s proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the PHP system is being developed
under the tradename HEPZATO KIT (melphalan hydrochloride for
injection/hepatic delivery system), or HEPZATO, for the treatment
of metastatic ocular melanoma (mOM), also known as metastatic uveal
melanoma (mUM) and is considered a combination drug and device
product regulated by the United States Food and Drug Administration
(FDA).
In Europe, the PHP system is regulated as a Class IIb medical
device and is approved for sale under the trade name CHEMOSAT
Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has
been used at major medical centers to treat a wide range of cancers
of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James
Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jul 2023 to Jul 2024